ReviewMolecular medicine reports2026
SIRT1/AMPK/PGC1α pathway in ischemic stroke: Elucidating neuroprotective strategies (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased prevalence of stroke around the globe is a notable challenge as there are few treatments and the long‑term effects include neurological impairment. Oxidative stress, mitochondrial dysfunction and neuroinflammation are key mechanisms underlying the complex pathophysiology of stroke, yet their precise interactions remain poorly understood. Notably, the silent information regulator 2 homolog 1 (SIRT1)/AMP‑activated protein kinase (AMPK)/peroxisome proliferator‑activated receptor γ coactivator 1‑α (PGC1α) pathway contributes to the neuronal protection against stroke damage. The possible beneficial effects through modulations of this pathway are explored in the present review, in particular, how flavonoids may provide a promising solution to reducing the consequences of stroke. Over the years, there has been a focus on treatments using alternative methods, leaving behind the traditional drugs‑based approaches. These involve researching the impacts of physical activity and caloric intake and assessing the possible advantages of naturally available products. This versatile approach provides new prospects of therapeutic development. The present comprehensive review aimed to understand the complexity of SIRT1/AMPK/PGC1α pathway with the aim to identify potential multi‑target therapeutic approaches to reduce the notable effects of stroke on global health and wellbeing and offer new promise in the current management of ischemic stroke. The present review demonstrates that SIRT1/AMPK/PGC1α is a key neuroprotective target in stroke. Moreover, it reveals that flavonoids combined with exercise and caloric restriction enhance treatment, and that flavonoid nanoparticles crossing the blood‑brain barrier offer neuroprotection. Finally, the review focuses on brain PGC1α, improved delivery and trials performed to advance stroke therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.